ArticleNPJ precision oncology2026
Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Pheochromocytoma (PCC) and paraganglioma (PGL) are neuroendocrine tumors derived from chromaffin cells of the adrenal medulla and ganglia of the autonomic nervous system. Approximately one-third are causatively associated with pathogenic germline variants. Metastatic disease develops in up to 25% of patients with PCC/PGL, for whom therapeutic options are limited, and no targeted treatments exist. Tumor evolution in metastatic PCC/PGL has not been well delineated. We performed whole-exome sequencing of paired specimens from 27 patients with metastatic PCC/PGL to better understand cancer progression. Tumors demonstrate high rates of loss-of-function variants in chromatin remodeling and DNA damage repair genes, suggesting potential therapeutic targets. Low rates of shared somatic variants were observed between primary tumors and metastases, with evidence of independent monoclonal pathogenic variants in metastatic tumors. These findings suggest that PCC/PGL metastases develop via monoclonal seeding and parallel progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.